Minnesota officials describe CRE caused by uncommon pathogens
Although carbapenemase-producing carbapenem-resistant Enterobacteriaceae (CP-CRE) involving Escherichia coli, Klebsiella, and Enterobacter cause the most mortality and other clinical impact, CRE associated with less common genera may also cause detrimental infections, researchers with the Minnesota Department of Health (MDH) reported today in Morbidity and Mortality Weekly Report (MMWR).
CRE from less common genera have generally not been targeted for carbapenemase testing, the authors note, in part because some of them have intrinsic resistance to the carbapenem imipenem (IMP) and others express species-specific chromosomal carbapenemases. But the less common CRE organisms can also harbor plasmid-mediated carbapenemases.
The investigators found that 149 (12.0%) of 1,241 CRE isolates tested at the MDH Public Health Laboratory from Jan 1, 2014, through Sep 30, 2017, were CP-CRE. All were from different patients. Of the 149 CRE, 20 (13.4%) were from less common genera. The most common species were IMP-producing Providencia rettgeri (7 isolates) and Klebsiella pneumoniae carbapenemase (KPC)-producing Citrobacter freundii (6).
Among the 20 patients, median age was 56.5 years (range, 14 to 75 years), and 15 patients were hospitalized at the time of culture collection. Two patients were hospitalized internationally—one in Kenya, one in Kuwait—in the year before they tested positive.
The authors concluded, "Less common Enterobacteriaceae genera appear to be a small but potentially important subset of CP-CRE; however, estimates of the true proportion of CP-CRE from these less common genera are limited by the lack of systematic testing. Of note, many of the carbapenemases in the less common CRE genera were not KPC."
Jun 15 MMWR report
Advocates say hospital pharmacists strengthen stewardship programs
The European Association of Hospital Pharmacists (EAHP) is calling for a greater role for pharmacists in antibiotic stewardship programs.
In a position paper on antimicrobial resistance (AMR) issued yesterday, the group calls on national governments and health system managers to "utilise the specialized background and knowledge of the hospital pharmacists in multi-professional antibiotic stewardship teams," arguing that pharmacists can help enforce stewardship and promote prudent use of antimicrobial drugs.
Among the ways that pharmacists can strengthen stewardship programs, the group says, is through reviewing antibiotic duration, advising on the cessation of appropriate antibiotic treatment, and educating other healthcare professionals on restricted use of certain antibiotics.
Other recommendations in the position paper include universal application of infection and prevention control measures, regulatory oversight of antibiotic use in the livestock and agriculture sector, and increased investment to support the development of new antibiotics and new fields of infectious disease control. The EAHP also urges governments to make arrangements to maintain essential antibiotics on the market and prevent shortages.
Jun 13 EAHP position paper